ArticleScientific reports2019
An emerging trend of rapid increase of leukemia but not all cancers in the aging population in the United States.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed, 90 citations in OpenAlex.
- Incidence rates of non-Hodgkin lymphoma subtypes among Black Africans with and without HIV in South Africa: a national registry-based study.The Lancet regional health. Africa · 2026Article
- Hematopoietic (stem) cells-The elixir of life?FEBS letters · 2026Review
- Leukemia Incidence and Demographic Trends in Saudi Arabia, 1997-2022: A Nationwide Registry Analysis.Journal of epidemiology and global health · 2025Article
- Aging with leukemia: public health strategies for optimizing quality of life and palliative care in refractory cases.Annals of medicine and surgery (2012) · 2025Review
- Article
- Emerging nanocarriers as advanced delivery tools for the treatment of leukemia.Nanomedicine (London, England) · 2025Review
- Synthesis and Biological Evaluation of Quercetagetin Derivatives as the Inhibitors of Mcl-1 and Bcl-2 Against Leukemia.International journal of molecular sciences · 2025Article
- Regional, demographic, and temporal trends in myeloid leukemia mortality in the United States (1999-2022): a comprehensive analysis using CDC WONDER.Frontiers in oncology · 2025Article
- Splicing the Difference: Harnessing the Complexity of the Transcriptome in Hematopoiesis.Experimental hematology · 2024Review
- Age-associated myeloid malignancies - the role of STAT3 and STAT5 in myelodysplastic syndrome and acute myeloid leukemia.FEBS letters · 2024Review
- Comparison of Epstein-Barr virus copy number in white blood cells of chronic lymphocytic leukemia patients with laboratory prognostic biomarker.BMC research notes · 2024Article
- Leukemia in India: Insights Into Incidence, Prevalence, Mortality, and Disability-Adjusted Life Years.Cureus · 2024Article
- Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications.European journal of medical research · 2024Review
- Obesity and Leukemia: Biological Mechanisms, Perspectives, and Challenges.Current obesity reports · 2024Review
- Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib.Future oncology (London, England) · 2024Article
- Cost-effectiveness of acalabrutinib monotherapy or with obinutuzumab versus chemoimmunotherapy for untreated chronic lymphocytic leukemia in China.Therapeutic advances in hematology · 2024Article
- Trends in childhood leukemia incidence in urban countries and their relation to environmental factors, including space weather.Frontiers in public health · 2024Article
- Impairment of vocational activities and financial problems are frequent among German blood cancer survivors.Scientific reports · 2023Article
- Survival of Patients with Acute Coronary Syndrome and Hematologic Malignancies-A Real-World Analysis.Cancers · 2023Article
- Burden of AML, 1990-2019: Estimates From the Global Burden of Disease Study.JCO global oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The "baby boomers" born in 1946-1964 in the United States (U.S.) started to reach the age of 65 in 2011, rapidly accelerating U.S. population aging. There are great public concerns about its impact on health care with anticipation of rising cancer incidences. We examined the incidences and deaths of leukemia and overall cancer in the U.S. from 1998 to 2018. The acute myeloid leukemia (AML) and chronic myeloid leukemia (CML) incidences remained constant prior to 2011 but have climbed up substantially since then, and the chronic lymphocytic leukemia (CLL) incidence has increased continuously since 1998. The significant increase of myeloid leukemia and CLL incidences was strongly correlated with the U.S. population aging. The incidence of all cancers was increased in correlation with a small increase in aging population prior to 2011, but surprisingly has changed marginally since 2011, which was not significantly correlated with the accelerated population aging. We observed the most substantial decline of deaths with CML, whereas AML deaths continued to rise in the past 20 years. In conclusion, the overall cancer incidence was not increased as fast as previously feared with aging Americans; however, the incidences of myeloid leukemia and CLL significantly outpaced that of all cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.